Taste alterations after radiotherapy for head and neck tumors: causes and approaches to management (a literature review)

Dysgeusia (taste alteration) is one of the most common complications of radiotherapy and chemoradiotherapy for head and neck malignant tumors, occurring in 70–96 % of cases. This review addresses the causes of this complication, which include direct damage to taste bud progenitor cells with suppression of signaling pathways, indirect taste impairment secondary to xerostomia and von Ebner's gland dysfunction, as well as the effects of inflammatory mechanisms and changes in the oral microbiome. The addition of systemic chemotherapy, primarily with cisplatin, exacerbates damage to taste structures through direct cytotoxicity and neurotoxicity. Key risk factors for dysgeusia are the dose burden to the oral cavity (≥ 40 Gy) and parotid glands, complex tumor localization, a history of glossectomy, and concurrent chemotherapy. Impairment of bitter taste perception is reported most frequently, whereas sweet taste is the least affected. Taste recovery is observed in the majority of patients by 6–12 months after completion of treatment; however, in 23–50 % of cases, taste disturbances persist in the long term and significantly reduce patients' quality of life. Prevention of dysgeusia is based on optimization of the radiotherapy dosimetric plan with inclusion of the dorsal surface of the tongue in the list of organs at risk, the use of intensity-modulated radiotherapy, volumetric modulated arc therapy and proton therapy, as well as the use of intraoral stents. Pharmacological prevention with zinc compounds has demonstrated inconsistent results. Rehabilitation of patients with dysgeusia requires a multidisciplinary approach that includes nutritional support, dietary modification, taste training and psychological support. The review systematizes current data on the pathophysiology, risk factors, methods of prevention and rehabilitation of dysgeusia arising during radiotherapy and chemoradiotherapy for head and neck tumors.

Authors

Institutions

Publication Details

Journal
Head and neck tumors (HNT)
Published
2026-11-20
DOI
https://doi.org/10.17650/2222-1468-2026-16-3-65-75
Primary Topic
Oral health in cancer treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Taste alterations after radiotherapy for head and neck tumors: causes and approaches to management (a literature review)

Игорь Александрович Гулидов, A. V. Semenov, Л. С. Мкртчян
Head and neck tumors (HNT)
Oral health in cancer treatment
article

Taste alterations after radiotherapy for head and neck tumors: causes and approaches to management (a literature review)

Игорь Александрович Гулидов, A. V. Semenov, Л. С. Мкртчян
article en

Abstract

Dysgeusia (taste alteration) is one of the most common complications of radiotherapy and chemoradiotherapy for head and neck malignant tumors, occurring in 70–96 % of cases. This review addresses the causes of this complication, which include direct damage to taste bud progenitor cells with suppression of signaling pathways, indirect taste impairment secondary to xerostomia and von Ebner's gland dysfunction, as well as the effects of inflammatory mechanisms and changes in the oral microbiome. The addition of systemic chemotherapy, primarily with cisplatin, exacerbates damage to taste structures through direct cytotoxicity and neurotoxicity. Key risk factors for dysgeusia are the dose burden to the oral cavity (≥ 40 Gy) and parotid glands, complex tumor localization, a history of glossectomy, and concurrent chemotherapy. Impairment of bitter taste perception is reported most frequently, whereas sweet taste is the least affected. Taste recovery is observed in the majority of patients by 6–12 months after completion of treatment; however, in 23–50 % of cases, taste disturbances persist in the long term and significantly reduce patients' quality of life. Prevention of dysgeusia is based on optimization of the radiotherapy dosimetric plan with inclusion of the dorsal surface of the tongue in the list of organs at risk, the use of intensity-modulated radiotherapy, volumetric modulated arc therapy and proton therapy, as well as the use of intraoral stents. Pharmacological prevention with zinc compounds has demonstrated inconsistent results. Rehabilitation of patients with dysgeusia requires a multidisciplinary approach that includes nutritional support, dietary modification, taste training and psychological support. The review systematizes current data on the pathophysiology, risk factors, methods of prevention and rehabilitation of dysgeusia arising during radiotherapy and chemoradiotherapy for head and neck tumors.

Head and neck tumors (HNT)Vol. 16(3)
Ministry of Health of the Russian Federation (RU), Medical Radiological Research Center (RU)
Oral health in cancer treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon